STATE-OF-THE-ART PAPER
Contrast nephropathy: Review focusing on prevention
Micha Maeder, MD*,*,
Maja Klein, MD ,
Thomas Fehr, MD and
Hans Rickli, MD*
* Division of Cardiology, Department of Internal Medicine
Division of General Internal Medicine, Department of Internal Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland
Transplantation Biology Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA
Manuscript received April 26, 2004;
revised manuscript received May 30, 2004,
accepted June 22, 2004.
* Reprint requests and correspondence: Dr. Micha Maeder, Division of Cardiology, Department of Internal Medicine, Kantonsspital St. Gallen, Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland (Email: micha.maeder{at}kssg.ch).
Contrast nephropathy (CN) accounts for significant morbidity and mortality. Patients with pre-existing renal insufficiency, especially those with diabetic nephropathy, are at particular risk. Medullary hypoxia due to decreased renal blood flow and direct cytotoxicity contribute to the pathogenesis. Contrast nephropathy is usually defined as an increase in serum creatinine concentration >0.5 mg/dl or 25% above the baseline level within 48 h. Intravenous hydration (saline 0.45%, if tolerated 0.9% at a rate of 1 ml/kg/h) 12 h before and after contrast exposure and the use of low or iso-osmolality contrast agents are advisable. The benefit of low-dose dopamine as well as the selective dopamine-1 receptor agonist fenoldopam is unproven. Studies on the effectiveness of the adenosine antagonist theophylline have led to conflicting results. Because theophylline has a narrow therapeutic range and may be associated with adverse effects, it is not a prophylactic agent of first choice. The administration of N-acetylcysteine (NAC) has been evaluated in several trials with inconsistent results. Newer data suggest a benefit of high-dose NAC (1,200 mg twice daily) for patients receiving high doses (>140 ml) of contrast agent, or those with advanced renal insufficiency (creatinine >2.5 mg/dl). Whereas prophylactic hemodialysis does not prevent CN, a recent study demonstrated a marked benefit of prophylactic hemofiltration.
|
Abbreviations and Acronyms
| | ACEI = angiotensin-converting enzyme inhibitor | | A2 = adenosine-2-receptor | | CN = contrast nephropathy | | DA1 = dopamine-1-receptor | | NAC = N-acetylcysteine | | NSAID = non-steroidal anti-inflammatory drug |
|
This article has been cited by other articles:
|
|
|
|
 
M. Maioli, A. Toso, M. Leoncini, M. Gallopin, D. Tedeschi, C. Micheletti, and F. Bellandi
Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention
J. Am. Coll. Cardiol.,
August 19, 2008;
52(8):
599 - 604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Klein, B. M. Massie, J. D. Leimberger, C. M. O'Connor, I. L. Pina, K. F. Adams Jr, R. M. Califf, M. Gheorghiade, and for the OPTIME-CHF Investigators
Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF)
Circ Heart Fail,
May 1, 2008;
1(1):
25 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. From, B. J. Bartholmai, A. W. Williams, S. S. Cha, A. Pflueger, and F. S. McDonald
Sodium Bicarbonate is Associated with an Increased Incidence of Contrast Nephropathy: A Retrospective Cohort Study of 7977 Patients at Mayo Clinic
Clin. J. Am. Soc. Nephrol.,
January 1, 2008;
3(1):
10 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. K. Laskey, C. Jenkins, F. Selzer, O. C. Marroquin, R. L. Wilensky, R. Glaser, H. A. Cohen, D. R. Holmes Jr, and for the NHLBI Dynamic Registry Investigators
Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
584 - 590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Eur. Heart J.,
July 1, 2007;
28(13):
1598 - 1660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Park, B.-K. Koo, H.-L. Kim, Y.-S. Kim, S.-H. Jo, H.-Y. Lee, H.-J. Kang, Y.-S. Cho, W.-Y. Chung, T.-J. Yeon, et al.
The incidence and predictors of contrast-induced nephropathy in adequately hydrated elderly patients with impaired renal function
Nephrol. Dial. Transplant.,
June 1, 2007;
22(6):
1794 - 1795.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Recio-Mayoral, M. Chaparro, B. Prado, R. Cozar, I. Mendez, D. Banerjee, J. C. Kaski, J. Cubero, and J. M. Cruz
The Reno-Protective Effect of Hydration With Sodium Bicarbonate Plus N-Acetylcysteine in Patients Undergoing Emergency Percutaneous Coronary Intervention: The RENO Study
J. Am. Coll. Cardiol.,
March 27, 2007;
49(12):
1283 - 1288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-H. Jo, T.-J. Youn, B.-K. Koo, J.-S. Park, H.-J. Kang, Y.-S. Cho, W.-Y. Chung, G.-W. Joo, I.-H. Chae, D.-J. Choi, et al.
Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography: The RECOVER Study: A Randomized Controlled Trial
J. Am. Coll. Cardiol.,
September 5, 2006;
48(5):
924 - 930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Pannu, N. Wiebe, M. Tonelli, and for the Alberta Kidney Disease Network
Prophylaxis Strategies for Contrast-Induced Nephropathy
JAMA,
June 21, 2006;
295(23):
2765 - 2779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tepel, P. Aspelin, and N. Lameire
Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach
Circulation,
April 11, 2006;
113(14):
1799 - 1806.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Claus, R. Schmitt, C. Stabroth, F. C. Luft, R. Kettritz, and C. M. Gross
Where do we stand with renovascular hypertension?
Nephrol. Dial. Transplant.,
July 1, 2005;
20(7):
1495 - 1498.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Messiou and A G Chalmers
Imaging in acute pancreatitis
Imaging,
September 1, 2004;
16(4):
314 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
